Katherine Ruffner MD
About Katherine Ruffner MD
Katherine Ruffner, MD, serves as the Executive Director at Orano Med, where she applies her extensive experience in clinical development and oncology. She has held various leadership roles in prominent pharmaceutical companies, contributing to the development of small molecules and antibody drug conjugates.
Work at Orano Med
Katherine Ruffner currently serves as the Executive Director at Orano Med, a position she has held since 2024. In this role, she is responsible for overseeing clinical development initiatives and strategic planning within the organization. Her leadership is focused on advancing oncology treatments and enhancing patient outcomes through innovative approaches.
Education and Expertise
Katherine Ruffner completed her medical degree (MD) at The University of Tennessee Health Science Center. She furthered her education with a fellowship in Medical Oncology at the Fred Hutchinson Cancer Research Center/University of Washington. Additionally, she completed her residency in Internal Medicine at the University of Michigan and earned a Bachelor of Science in Biology from Duke University. Her educational background supports her extensive expertise in clinical development and oncology.
Background
Katherine Ruffner has a diverse professional background in the pharmaceutical and biotechnology sectors. She has held various leadership positions, including Director of the Oncology Business Unit at Pfizer and Senior Director of Clinical Development at Seattle Genetics and Medivation. Her career spans multiple organizations, where she has contributed to the development of cancer therapies and clinical strategies.
Achievements
Throughout her career, Katherine Ruffner has authored numerous abstracts, posters, and presentations for major oncology congresses such as ASH, ASCO, and EHA. She has been involved in publication planning and the review of promotional materials as part of cross-functional teams. Additionally, she has authored regulatory documents, including Investigator's Brochures and Clinical Study Reports, and has engaged with regulatory authorities like the FDA and EMA.
Previous Work Experience
Katherine Ruffner has held significant roles in various organizations prior to her current position. She worked as Vice President at Bristol Myers Squibb, leading lymphoma development from 2022 to 2023. Her previous experience includes serving as Chief Medical Officer at Cardiff Oncology and Vice President at ALX Oncology. She also worked at Array BioPharma, CTI BioPharma, and other companies, contributing to clinical development and strategic planning in oncology.